Atay Oguzhan sold $523K of BLLN (indirect holdings)
Atay Oguzhan (Chairman and CEO) sold 5,332 indirectly-held shares of BillionToOne, Inc. (BLLN) at $98.00 ($0.52M total) across 2 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The sale is modest and likely already priced in; traders should not adjust positions based solely on this filing.
Market read
Low relevance; typical insider sale with limited market effect.
What to watch
Potential upcoming financing needs or dilution not disclosed.
Background
Form 4 filing discloses insider transactions; BLLN is a micro‑cap biotech.
Ticker impact
Chairman and CEO sold 5,332 shares for $522,536 via a 10b5-1 plan on 2026-09-14.
Limited short-term pressure; unlikely to move price materially.
The transaction is a routine 10b5-1 sale of less than $1M, typical for insiders; market impact is expected to be minimal.
Market effects
No direct sector impact; biotech sector unchanged.
U.S. market only; no regional ripple.
Not globally relevant.
Counterpoint
If the insider holds significant knowledge, the sale could hint at upcoming challenges.
Key entities
- CompanyBillionToOne, Inc.
Biotech firm listed on NASDAQ under ticker BLLN.
- InsiderAtay Oguzhan
Chairman and CEO of BillionToOne, Inc.

